KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Short-term Investments (2017 - 2026)

Guardant Health's Short-term Investments history spans 9 years, with the latest figure at $823.4 million for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 161.86% to $823.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $823.4 million, a 161.86% increase, with the full-year FY2025 number at $823.4 million, up 161.86% from a year prior.
  • Short-term Investments hit $823.4 million in Q4 2025 for Guardant Health, up from $314.4 million in the prior quarter.
  • Over the last five years, Short-term Investments for GH hit a ceiling of $1.1 billion in Q1 2021 and a floor of $35.1 million in Q4 2023.
  • Historically, Short-term Investments has averaged $637.5 million across 5 years, with a median of $697.5 million in 2023.
  • Biggest five-year swings in Short-term Investments: plummeted 95.96% in 2023 and later surged 795.91% in 2024.
  • Tracing GH's Short-term Investments over 5 years: stood at $440.5 million in 2021, then soared by 97.39% to $869.6 million in 2022, then plummeted by 95.96% to $35.1 million in 2023, then surged by 795.91% to $314.4 million in 2024, then skyrocketed by 161.86% to $823.4 million in 2025.
  • Business Quant data shows Short-term Investments for GH at $823.4 million in Q4 2025, $314.4 million in Q4 2024, and $310.7 million in Q3 2024.